Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients
Clinical Pharmacokinetics · 2023
DOI: 10.1007/s40262-023-01270-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2023. Verfasst von Sarah Lobet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Inserm UMR 1069, Nutrition Croissance et Cancer (N2C), Tours University, Tours, France. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal immunoglobulin (Ig)G1 antibody, has been approved for the treatment of metastatic colorectal cancer (mCRC). The influence of target-antigen on cetuximab pharmacokinetics has never been investigated using target-mediated drug disposition (TMDD) modelling. This study aimed to investigate the relationship between cetuximab concentrations, target kinetics and progression-free survival (PFS). METHODS: In this ancillary study (NCT00559741), 91 patients with mCRC treated with cetuximab were assessed. Influence of target levels on cetuximab pharmacokinetics was described using TMDD modelling. The relationship between cetuximab concentrations, target kinetics and time-to-progression (TTP) was described using a joint pharmacokinetic-TTP model, where unbound target levels were assumed to influence hazard of progression by an Emax model. Mitigation strategies of concentration-response relationship, i.e., time-varying endogenous clearance and mutual influences of clearance and time-to-progression were investigated. RESULTS: Cetuximab concentration-time data were satisfactorily described using the TMDD model with quasi-steady-state approximation and time-varying endogenous clearance. Estimated target parameters were baseline target levels (R0 = 43 nM), and complex elimination rate constant (kint = 0.95 day-1). Estimated time-varying clearance parameters were time-invariant component of CL (CL0= 0.38 L/day-1), time-variant component of CL (CL1= 0.058 L/day-1) and first-order rate of CL1 decreasing over time (kdes = 0.049 day-1). Part of concentration-TTP was TTP-driven, where clearance and TTP were inversely correlated. In addition, increased target occupancy was associated with increased TTP. CONCLUSION: This is the first study describing the complex relationship between cetuximab target-mediated pharmacokinetics and PFS in mCRC patients using a joint PK-time-to-progression model. Further studies are needed to provide a more in-depth description of this relationship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Inserm UMR 1069, Nutrition Croissance et Cancer (N2C), Tours University, Tours, France.
- EA4245 Transplantation, Immunologie, Inflammation (T2i), Tours University, Tours, France.
- Centre Pilote de suivi Biologique des traitements par Anticorps (CePiBAc), Tours University Hospital, Tours, France.
- Pharmacology-Toxicology Department, Tours University Hospital, Tours, France.
- PRC, INRAe UMR85, CNRS UMR7247, Tours University, Nouzilly, France.
- Oncopharmacology-Pharmacogenetics Department INSERM U892, Institut de Cancérologie de l'Ouest site Paul Papin, Angers, France.
ORCID-Profile: David Ternant
Zitieren
APA
Lobet, S., Paintaud, G., Azzopardi, N., Passot, C., Caulet, M., Chautard, R., Desvignes, C., Capitain, O., Tougeron, D., Lecomte, T., & Ternant, D. (2023). Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-023-01270-2
Vancouver
Lobet S, Paintaud G, Azzopardi N, Passot C, Caulet M, Chautard R, et al. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics. 2023. doi:10.1007/s40262-023-01270-2
BibTeX
@article{Lobet2023,
author = {Lobet, Sarah and Paintaud, Gilles and Azzopardi, Nicolas and Passot, Christophe and Caulet, Morgane and Chautard, Romain and Desvignes, Céline and Capitain, Olivier and Tougeron, David and Lecomte, Thierry and Ternant, David},
title = {Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients},
journal = {Clinical Pharmacokinetics},
year = {2023},
doi = {10.1007/s40262-023-01270-2}
}
EUVIMED